Symkevi-Kalydeco Combo Approved in Europe to Treat CF Patients Ages 6–11

Symkevi-Kalydeco Combo Approved in Europe to Treat CF Patients Ages 6–11
5
(3)

The European Commission has approved the combination of Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor) for the treatment of children, ages 6 to 11, with cystic fibrosis (CF) carrying certain genetic mutations.

Eligible children must carry either two copies of the F508del mutation — the most common mutation associated with CF — in the CFTR gene, or one copy of the F508del mutation along with one copy of 14 other mutations that are known to nearly eliminate the activity of the CFTR protein. A complete list of all mutations that are amenable to treatment can be found here.

This combination therapy had previously been approved in the European Union to treat CF patients, 12 and older, carrying the same mutations in the CFTR gene.

The European Commission’s decision to approve the combination therapy for younger children was announced shortly after the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency, recommended Symkevi be approved to treat children as young as 6.

“With this approval, children with CF in Europe ages 6 to 11 years with the most common mutation, F508del, have a new treatment option and children with certain residual function mutations will, for the first time, have a treatment option available that addresses the underlying cause of their CF,” Reshma Kewalramani, MD, president and CEO of Vertex Pharmaceuticals, the therapies’ developer, said in a press release.

The combination of Symkevi (known as Symdeko in the U.S.) and Kalydeco will immediately be available to eligible children in Germany, and will soon be available to those living in other European countries, including Denmark, the U.K., and the Republic of Ireland, that have entered into long-term reimbursement agreements with Vertex.

Vertex stated it will work closely with European regulatory authorities to ensure eligible children living in other countries will also have access to the treatment.

“Today’s approval brings us closer to our ultimate goal of providing medicines for all people with CF,” Kewalramani said.

Symkevi and Kalydeco are two CF therapies designed to tackle specific defects in the CFTR protein that prevent it from performing its normal function.

Tezacaftor, one of Symkevi’s active ingredients, is a CFTR corrector designed to counteract the effects of mutations that interfere with the normal folding of the CFTR protein and that prevent the protein from reaching the cells’ surface where it acts as a channel transporting water and chloride in and out of cells.

Conversely, ivacaftor, Kalydeco’s active ingredient, is a CFTR potentiator that is designed to keep the CFTR protein in a stable conformation after it reaches the cells’ surface, to further improve its function.

In Europe, Kalydeco is also approved as a stand-alone therapy to treat infants with CF as young as 6 months. In September, the CHMP also recommended Kalydeco’s approval be extended to allow the therapy to be given to infants as young as four months.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • PhD program
  • Pravibismane and CFF grant
  • treatment burden and CF
  • vitamin D study

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 3

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?